

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629

Status	RECRUITING
Phase	Phase 3
Sponsor	Intellia Therapeutics
Enrollment	1,200 participants

Key Eligibility Criteria

Inclusion (4)

- Documented diagnosis of ATTR amyloidosis with cardiomyopathy
- Medical history of heart failure (HF)
- Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention
- Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 600 pg/mL and less than 10,000 pg/mL

Exclusion (10)

- New York Heart Association (NYHA) Class IV HF
 - Polyneuropathy Disability score of IV (confined to wheelchair or bed)
 - Has hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
 - History of active malignancy within 3 years prior to screening
 - RNA silencer therapy (patisiran, inotersen and/or eplontersen) within 12 months prior to dosing. Any prior vutrisiran use is not allowed
- ... and 5 more (see full listing online)

Locations (132 total)

University of Arizona, Tucson, Arizona, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Western Greater Los Angeles VA Medical Center, Los Angeles, California, United States
... and 129 more locations